Home » Classic Medicine » Pharmacology » mifamurtide


mifamurtide image from New Medical Terms



A synthetic lipophilic derivative of muramyl dipeptide, an immune stimulatory component of mycobacterial cell walls. It is approved in Europe to manage high-grade, non-metastasising, resectable osteosarcoma after surgical excision in patients age 2 to 30.

Adverse effects Fever–90%, tachycardia–50%, constipation–10%, vomiting, fatigue, infections, anaemia, anorexia, headache, diarrhoea.

Prognosis Mifamurtide-treated patients have a 30% lower mortality than those treated with chemotherapy alone. 

Mechanism This agent simulates a bacterial infection by binding to NOD2, a so-called pattern recognition receptor, activating white cells, triggering increased production of TNF-α, IL1, IL6, IL8, IL12, and other cytokines, as well as ICAM-1. The activated white cells attack cancer cells

Synonyms Liposomal muramyl tripeptide phosphatidyl ethanolamine, Mepact® 

Reference http://en.wikipedia.org/wiki/Mifamurtide


Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.